Bayer/Onyx initiate Ph III Nexavar trial in liver cancer
Germany's Bayer HealthCare and the USA's Onyx Pharmaceuticals have initiated a new Phase III trial of Nexavar (sorafenib) in liver cancer.
The randomized, double-blind, placebo-controlled study is evaluating the agent as an adjuvant therapy for patients with hepatocellular carcinoma, or primary liver cancer. An adjuvant treatment is given as an additional systemic therapy after the initial tumor treatment.
The STORM trial aims to further build on earlier Phase III data, which demonstrated a significant improvement in overall survival in patients with unresectable liver cancer and led to its approval for HCC in the USA and Europe at the end of last year (Marketletter November 5, 2007).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze